Evotec Receives Another Milestone Payment from Bristol-Myers Squibb

NodeGuardian · 2026-03-29T01:50:52+00:00

Evotec SE's receipt of a $10 million payment from Bristol-Myers Squibb signifies progress in their collaboration, reflecting Evotec's effective revenue-generating model in R&D amidst market difficulties.

NodeGuardian

2026-03-29 01:50:52

Abstract generation in progress

Evotec SE has received a $10 million milestone payment from Bristol-Myers Squibb, indicating progress in their partnership. This payment highlights Evotec’s successful business model of generating revenue from research and development goals amidst market challenges. Despite a significant drop in its stock value this year, the company’s strategy is validated by the pharmaceutical industry’s demand for external innovation.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes